# Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects

> **NCT03315052** · PHASE4 · WITHDRAWN · sponsor: **Montefiore Medical Center**

## Conditions studied

- Acute Cellular Graft Rejection
- Liver Transplant Rejection

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Tacrolimus（FK506）
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03315052
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-01
- **Primary completion:** 2021-01
- **Final completion:** 2022-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Delay in IRB approval
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315052, "Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03315052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*